Arvinas Inc.
Clinical-stage biotech Arvinas uses PROTAC technology, with Phase‑3 Bavdegalutamide/ARV‑766 for metastatic prostate and ARV‑471 for ER+/HER2+ breast. Early‑stage ARV‑393, ARV‑102, KRAS G12D preclinical; supported by Pfizer, Roche, Genentech, Bayer.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 430
- HQ: New Haven
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.